Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DLBS1033 in Acute Ischemic Stroke
NCT02133521Phase 3Terminated
- Sponsor
- Dexa Medica
- Start
- Nov 2014
- Primary completion
- Feb 2023
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing DLBS1033 with Placebo (2 arms). Primary endpoints: National Institutes of Health Stroke Scale at 28 days and Barthel Index at 28 days. Started Nov 2014; status: terminated.
02
Drugs
DLBS1033
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02133521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02133521.